Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif® New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

49 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-01-31

Study Completion Date

2013-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This observational multicentric study is planned to assess the tolerability of Rebif New Formulation in an Australian clinical setting by the incidence of injection site reactions (ISRs). The study will allow the comparison of tolerability data with historical data for both Rebif New and classic formulations, and will do so by using the same pre- specified preferred terms of treatment emergent adverse events as done in historical studies. In addition, the study will analyse whether interaction(s) with a nurse impacts tolerability and the impact of Rebif New Formulation on the patient's Quality of Life.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Evaluate Rebif® New Formulation (Interferon-beta-1a) in Relapsing Remitting Multiple Sclerosis

NCT00441103

Multiple Sclerosis, Relapsing-Remitting

COMPLETED PHASE3

A Study of Rebif® in Subjects With Relapsing Multiple Sclerosis

NCT02064816

Multiple Sclerosis, Relapsing-Remitting

COMPLETED PHASE4

Post-Authorization Observational Study to Evaluate Cognition and Fatigue in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Treated With Rebif®

NCT01075880

Multiple Sclerosis, Relapsing-Remitting

COMPLETED

Safety, Tolerability and Adherence With Rebif® New Formulation in Real Life Settings (STAR)

NCT01080027

Multiple Sclerosis, Relapsing Remitting

COMPLETED

Transition to Rebif New Formulation

NCT00619307

Relapsing Multiple Sclerosis

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The disease-modifying therapies for multiple sclerosis (MS) aim to slow down the disease process and consequent damage to central nervous system. This study is an open-label, multicentric study planned to assess the tolerability of Rebif New Formulation in an Australian clinical setting by the incidence of ISRs. A total of 100 subjects having relapsing MS across approximately 20 sites in Australia will be enrolled into the study. Subject visits will be scheduled at baseline (month 0) and months 3, 6, 9 and 12 and the data related to demographic factors, disease history, quality of life and adverse drug reactions (ADRs) will be recorded in the case report form (CRF).

OBJECTIVES

Primary Objective:

* To assess the tolerability of Rebif New Formulation in an Australian clinical setting by the incidence of ISRs

Secondary Objectives:

* Observe the number of and reasons for missed injections of Rebif New Formulation at 3, 6, 9 and 12 months
* Assess changes in quality of life \[Multiple Sclerosis International Quality of Life Questionaire (MusiQoL)\] at 6 and 12 months compared to baseline
* Number and type (telephone, face-to-face, written) of interactions with nurse support at 3, 6, 9 and 12 months.
* Assess relapse rate at 12 months
* Assess any differences in tolerability of Rebif New Formulation between subjects who were treatment naïve or on previous MS therapy
* Observe the proportion of subjects with dose reductions to 22 mcg as a result of tolerability

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Multiple Sclerosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Interferon beta-1a (Rebif)

Interferon beta-1a 44 micrograms (12 MIU) given three times per week (tiw) by subcutaneous injection (SCI). Dose to be reduced to 22 micrograms (6 MIU) tiw by SCI for subjects who cannot tolerate the higher dose.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Rebif New Formulation

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Ambulatory patients with Multiple Sclerosis who:

1. have experienced two or more relapses within the last 2 years. or
2. are not tolerating their current MS therapy.
* Patients 18 years of age or over.
* Patients with Expanded Disability Status Scale (EDSS) score \<6.0.
* Patients who have given informed consent to participate in the study.

Exclusion Criteria

* Subjects with diagnosis of any other form of MS other than relapsing MS.
* Contra-indicated medical conditions for IFN beta-1a as defined in the Product Information i.e: women who are or plan to become pregnant whilst on therapy; subject with severe depressive disorders and/or suicidal ideation and; epileptic subjects with seizures not adequately controlled by treatment
* Subjects with a known hypersensitivity to natural or recombinant interferon beta, mannitol, poloxamer, methionine, sodium acetate buffer or benzyl alcohol.
* Subjects who are pregnant and/or breastfeeding.
* Subjects currently on Rebif New Formulation.
* Subjects currently experiencing a relapse.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No